Belite Bio
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12750 High Bluff Dr Ste 475, San Diego, ...Phone Number
(858) 246-6240Website
www.belitebio.comRevenue
-Stock Symbol
BLTEIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Belite Bio
Belite Bio is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. They are based in San Diego, California.Explore more
Belite Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Belite Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Belite Bio launches new products
Check out if Belite Bio is spiking on competitors!
Funding: Get notified immidiatlly once Belite Bio has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Belite Bio had a recent Job posting/layoffs
Earning: See what the market has to say on Belite Bio recently announced quarterly report
Check if Belite Bio has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Belite Bio
Belite Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Belite Bio as Masked Content
Find 3 more new buyers
Compare Similar Companies to Belite Bio
Compare insights from companies similar to Belite Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Belite Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Belite Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Belite Bio.
Belite Bio Tech Stack
A closer look at the technologies used by Belite Bio
Most Recent Scoops
Project
demonstrated in preclinical studies using mouse models that reducing RBP4 by 80% with the equivalent dose of 5 milligrams per day Tinlarebant can completely stop photoreceptor degeneration in a double knockout mouse model (RDH8 plus ABCA4), essentially rescuing the Stargardt disease model.
Medical Research, Pharmaceuticals
Project
reported that Tinlarebant's treatment emergent adverse events were primarily ophthalmic and aligned with its mechanism of action, including delayed dark and light adaptation (5 to 10 minutes longer to reach final threshold in darkness) and visual scene discoloration. Approximately one-third of patients experienced xanthopsia or dyschromatopsia lasting seconds or minutes, and another third noticed longer dark adaptation times, with almost all events rated as mild and many resolving over time.
Pharmaceuticals, Clinical Operations
Product Launch
Belite Bio has developed Tinlarebant as an oral, once-daily pill for Stargardt disease treatment. This represents a novel systemic approach in retinal medicine, where most products over the last 20 years have been eye-specific injections, devices, or surgical approaches, and provides simultaneous treatment effect in both eyes.
Product Development, Medical Research, Pharmaceuticals
Project
implemented the PROSTAR natural history study in 2014, funded by Foundation Fighting Blindness, which enrolled 291 patients across 10 centers worldwide with assessments every 6 months using imaging and visual function tests. The study successfully characterized the natural history of Stargardt disease and demonstrated that DDAF lesions could be precisely measured and their progression tracked, leading to FDA approval of this measure as an outcome endpoint.
Funding, Medical Research, Clinical Operations, Finance
Project
Medical Research, Clinical Operations
Belite Bio News & Media
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a panel discussion at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET.Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl said the company is advancing its lead compound, Tinlarebant, as a potential treatment for Stargardt disease and geographic atrophy secondary to age-related macular degeneration, two severe retinal diseases with overlapping features. SpeBelite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on Thursday, July 9, 2026, at 12:30 pm ET.Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Belite data will be presented at the 63rd Annual Symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV) being held on July 6-11, 2026, in Sydney, Australia, and the Americ
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Belite Bio
Sign Up For FreeTo access detailed company insights
Belite Bio is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. They are based in San Diego, California.... Read More
